{
    "paper_id": "fb98375058ffe9102b2151f602bc62f04b9e927a",
    "metadata": {
        "title": "Signaling Inhibitors in the COVID-19 Era?",
        "authors": []
    },
    "abstract": [],
    "body_text": [
        {
            "text": "that treatment with oral androgen receptor signaling 23 inhibitors (ARSIs) should not be stopped and that chemo-24 therapy should be replaced with an oral ARSI during the 25 COVID-19 pandemic [2] . 26 Although it is true that chemotherapy and radiotherapy 27 lead to suppression of the immune system, thus exposing 28 patients, especially those >70 yr of age, to a greater 29 infectious risk, and most chemotherapies induce neutrope-30 nia, affecting neutrophils, the body's first line of defense, I 31 believe that a warning regarding ARSIs is also necessary for 32 the three following reasons. ",
            "cite_spans": [
                {
                    "start": 192,
                    "end": 195,
                    "text": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 198,
                    "end": 200,
                    "text": "26",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "COVID-19: global consequences for oncology",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Editorial",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet Oncol",
            "volume": "21",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/S1470-2045(20)30175-3"
                ]
            }
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Advice for medical oncology care of Please cite this article in press as: Di G. Re: Silke Gillessen Sommer, Thomas Powles. Advice for Medical Oncology Care of Urological Cancer Patients During the COVID-19 Pandemic",
            "authors": [
                {
                    "first": "Gillessen",
                    "middle": [],
                    "last": "Sommer",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Powles",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Eur Urol. In press",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.eururo.2020.04.030"
                ]
            }
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": ", abiraterone, approved for hormone-sensitive and 34 castration-resistant prostate cancer, is always used in 35 combination with prednisone for several months, often in 36 elderly patients; the mechanisms that underlie the immu-37 nosuppressive properties of glucocorticoids have been well 38 recognized and described [3].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "of viral infection [4]; we now know that further 46 lymphopenia is a sequela of COVID-19. Third, it is important to remember that our cancer 48 patients often take numerous drugs for comorbidities, so an 49 analysis of drug interactions is indispensable. Enzaluta-50 mide, recognized as a strong CYP3A4 inducer and a 51 moderate CYP2C9 and CYP2C19 inducer, significantly 52 reduced concentrations of several anti-HIV agents such as 53 darunavir, ritonavir, etravirine, and raltegravir [5]; the latter 54 drugs are the subject of a series of trials in progress and 55 could be active in the fight against COVID-19.56 Finally, I suggest that chemotherapy or radiotherapy 57 should be weighted and postponed where possible, as 58 currently carried out daily in our hospital, but even ARSI 59 administration must be carefully monitored by discussing a 60 2-3-wk suspension and developing a protocol to fight the 61 virus that does not affect cancer outcomes.62Conflicts of interest: The author has nothing to disclose.",
            "latex": null,
            "type": "figure"
        }
    },
    "back_matter": []
}